

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Philippe G. Nantermet	
Serial No.:	To Be Assigned	Case No.: 21546YP
US Nat'l Filing Date:	March 23, 2006	
Int'l Appl'n No.	PCT/US2004/032009	
Int'l Filing Date:	September 29, 2004	
For:	BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT March 23, 2006
EXPRESS MAIL NO. EL989585-393 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY Kathy K. Lutkowski
DATE 3-23-06

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

References A and B on the accompanying PTO 1440 form were cited in the International Search Report for this application. A copy of the International Search Report and Written Opinion are enclosed with this Information Disclosure Statement.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: March 23, 2006

(use as many sheets as necessary)

COMPLETE IF KNOWN

To Be Assigned

10/573232

March 23, 2006

Philippe G. Nantermet

To Be Assigned

To Be Assigned

1

of

1

21546YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	D		WO 89/04833	PCT	The Upjohn Company	06/01/1989
	E		WO 01/00665	PCT	Oklahoma Medical Research Foundation	
					& Board of Trustees of the Univ. of Illinois	01/04/2001
	F		WO 2003/072535	PCT	Elan Pharmaceuticals and Pharmacia	
					& Upjohn Company	09/04/2003
	G		WO 02/02512	PCT	Elan Pharmaceuticals and Pharmacia	
					& Upjohn Company	01/10/2002

Date
Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005